Corporate | 17 July 2013 09:55
|
Geratherm Medical AG / Key word(s): Alliance
Together Against Stroke
Hamburg / Pirmasens, July 17, 2013 – By automated merging of patient information, apoplex medical technologies and Philips will take the next step in the battle against stroke. Particularly stroke patients with strokes of unknown origin could benefit from this. Undetected atrial fibrillation is considered to be a potential cause for stroke. Several methods for the detection of paroxysmal atrial fibrillation can help to confirm this assumption. With the fully automated ECG analysis for the detection of atrial fibrillation SRAclinic (SRA = Stroke Risk Analysis), developed by apoplex medical technologies, a method is now available, which is significantly superior to all previous standard methods. The ECG data for this analysis are provided for example by the patient monitoring system Philips IntelliVue. It records the patient data at the stroke unit and exports them pseudonymized at the touch of a button to the analysis server in the data center of apoplex medical technologies. There the data are analysed for paroxysmal atrial fibrillation (pxVHF) and summarized for the physician in a clearly arranged and expressive report. Based on this, a therapy with anticoagulants can be initiated, which reduces the risk for further strokes substantially. ‘A retrospective output function, integrated in the Philips IntelliVue Monitoring System, enables the transfer of up to 96 hours long term ECGs without additional interface effort’, explains Thomas Groß, Business Manager Patient Monitoring at Philips Healthcare Germany. This simplifies the clinical processes in a considerable extent. All stroke patients connected to a Philips Monitoring System are examined for atrial fibrillation during their complete bed time. There are no additional activities, neither for the physicians nor for the nursing staff, which could lead to further burden. As the data center of apoplex medical technologies is available to all hospitals, there are no additional technical requirements at the hospitals.
For Albert Hirtz, General Manager at apoplex medical technologies, it is obvious that patients and the health system equally benefit from such prevention: ‘each prevented stroke is a piece of luck for the people. And for the society it means a substantial reduction of costs in the end.’ In Germany 250.000 people suffer from stroke each year. In 35 to 40 percent of these strokes, the origin is not detectable.
Further information to SRAclinic at: www.apoplexmedical.com Further information to IntelliVue Patient Monitoring at: www.philips.de
About Royal Philips:
About apoplex medical technologies
apoplex medical technologies GmbH
End of Corporate News 17.07.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Geratherm Medical AG | |
| Fahrenheitstraße 1 | ||
| 98716 Geschwenda | ||
| Germany | ||
| Phone: | +49 (0)36205 98-0 | |
| Fax: | +49 (0)36205 98-1 15 | |
| E-mail: | info@geratherm.com | |
| Internet: | www.geratherm.com | |
| ISIN: | DE0005495626 | |
| WKN: | 549562 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 221568 17.07.2013 |